Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.
The mechanism of intestinal secretion of the difluorinated quinolone sparfloxacin was investigated with the epithelial cell line Caco-2 and was compared to that of the P-glycoprotein (P-gp) substrate vinblastine. The P-gp inhibitors verapamil and progesterone significantly increased the epithelial cell accumulation of both vinblastine and sparfloxacin. This increase is likely to result from an inhibition of drug secretion since both vinblastine uptake and sparfloxacin uptake are known to proceed through a passive transmembrane diffusion. The unidirectional fluxes across cell monlayers grown on permeable filters indicated that a net secretion of sparfloxacin and vinblastine occurred across Caco-2 cells. These secretions were significantly inhibited by the MDR-reversing agent verapamil. We conclude that the P-gp is likely to be involved in the intestinal elimination of the difluorinated quinolone sparfloxacin.
Cormet-Boyaka
E
E
INRA, Unité de Nutrition Humaine et de Physiologie Intestinale, Institut National Agronomique Paris-Grignon, 75005 Paris, France.
Huneau
J F
JF
Mordrelle
A
A
Boyaka
P N
PN
Carbon
C
C
Rubinstein
E
E
Tomé
D
D
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism*; D018938:Caco-2 Cells; D024841:Fluoroquinolones; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D015363:Quinolones / Q000378:metabolism*; D051381:Rats; D014747:Vinblastine / Q000493:pharmacokinetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D014747:Vinblastine; C061363:sparfloxacin